SMARCA4‑deficient non‑small cell lung cancer with an EGFR mutation: A case report
- Lijun Sun
- Qiong Fu
- Lijiang Chen
- Meijuan Di
- Jianhua Cao
Affiliations: Department of Pathology, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, Zhejiang 311200, P.R. China, Department of Respiratory Medicine, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, Zhejiang 311200, P.R. China
- Published online on: October 13, 2023 https://doi.org/10.3892/ol.2023.14100
Copyright: © Sun
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
SWI/SNF‑related, matrix‑associated, actin‑dependent regulator of chromatin, subfamily a, member 4 (SMARCA4)‑deficient non‑small cell lung cancer (dNSCLC) is a rare malignant tumor that originates in the lungs. It occurs more frequently in male smokers, and the epidermal growth factor receptor (EGFR) gene is often mutation‑free. In the present study, the case of a 60‑year‑old, non‑smoking female patient diagnosed with SMARCA4‑dNSCLC is reported. Biopsy of the tumor showed solid flaky, nest‑like infiltrating growth. Immunohistochemistry revealed the following: SMARCA4/BRG1(‑), SMARCB1/INI‑1(+), cytokeratin7 (+), cytokeratin 5.2 (+), CK5/6(+) and calretinin(+). The Ki‑67 positivity index was 75%, and the thyroid transcription factor‑1, NapsinA, p40, nuclear protein in testis, CD34, Sal‑like protein 4, SRY‑box transcription factor 2 and synaptophysin were negative. Molecular analysis showed mutations in both EGFR and TP53. The pathological diagnosis was SMARCA4‑dNSCLC with an EGFR gene mutation. The present case report could be used for broadening the pathological diagnosis of SMARCA4‑dNSCLC and for selecting appropriate treatment approaches.